Previous 10 |
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks finished modestly higher Friday on light pre-holiday volume following a late-session surge led by the energy sector, as crude oil futu...
Gainers: Bio-Path Holdings (BPTH) +253%.Cancer Genetics (CGIX) +74%.Torchlight Energy Resources (TRCH) +73%.CM Life Sciences (CMLF) +51%.India Globalization Capital (IGC) +42%.Anchiano Therapeutics (ANCN) +42%.The OLB Group (OLB) +41%.Sundial Growers (SNDL) +40%.Clever Lea...
Panbela Therapeutics (PBLA) shares slid nearly 30% premarket after announcing that an independent data safety monitoring board ((DSMB)) recommended that its treatment SBP-101 be held for ongoing patients in order to obtain additional safety information, following visual di...
MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a research agreement with the Johns Hopkins University School of...
Panbela is studying patients with pancreatic cancer testing investigative agent SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel Panbela’s independent data safety monitoring board (DSMB) recommended SBP-101 be held for ongoing pat...
Gainers: Ocugen OCGN +127%, CRH Medical CRHM +80%, Nemaura Medical NMRD +44%, aTyr Pharma (LIFE) +44%, Veru VERU +34%.Losers: ERYTECH Pharma ERYP -16%, Panbela Therapeutics (PBLA) -10%, Progenity PROG -9%, Ca...
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
Panbela Therapeutics Inc Com Website:
DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged Survival Rapid Enrollment P...
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference,...
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the q...